vs

Side-by-side financial comparison of Northwest Natural Holding Co (NWN) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Northwest Natural Holding Co is the larger business by last-quarter revenue ($394.2M vs $207.3M, roughly 1.9× Ultragenyx Pharmaceutical Inc.). On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 6.3%). Ultragenyx Pharmaceutical Inc. produced more free cash flow last quarter ($-100.8M vs $-131.0M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -4.6%).

NW Natural, formerly Northwest Natural Gas Company, is an American publicly traded utility headquartered in Portland, Oregon, United States. Primarily a natural gas distributor, the company services residential, commercial, and industrial customers in Western Oregon and Southwest Washington in the Pacific Northwest. NW Natural also owns water utilities. Founded in 1859, the company has approximately 800,000 customers and revenues of over $1 billion annually.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

NWN vs RARE — Head-to-Head

Bigger by revenue
NWN
NWN
1.9× larger
NWN
$394.2M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+19.6% gap
RARE
25.9%
6.3%
NWN
More free cash flow
RARE
RARE
$30.2M more FCF
RARE
$-100.8M
$-131.0M
NWN
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-4.6%
NWN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NWN
NWN
RARE
RARE
Revenue
$394.2M
$207.3M
Net Profit
$-128.6M
Gross Margin
Operating Margin
28.4%
-54.7%
Net Margin
-62.0%
Revenue YoY
6.3%
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$1.38
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NWN
NWN
RARE
RARE
Q4 25
$394.2M
$207.3M
Q3 25
$164.7M
$159.9M
Q2 25
$236.2M
$166.5M
Q1 25
$494.3M
$139.3M
Q4 24
$370.9M
$164.6M
Q3 24
$136.9M
$139.5M
Q2 24
$211.7M
$147.0M
Q1 24
$433.5M
$108.8M
Net Profit
NWN
NWN
RARE
RARE
Q4 25
$-128.6M
Q3 25
$-29.9M
$-180.4M
Q2 25
$-2.5M
$-115.0M
Q1 25
$87.9M
$-151.1M
Q4 24
$-133.2M
Q3 24
$-27.2M
$-133.5M
Q2 24
$-2.8M
$-131.6M
Q1 24
$63.8M
$-170.7M
Operating Margin
NWN
NWN
RARE
RARE
Q4 25
28.4%
-54.7%
Q3 25
-7.5%
-106.9%
Q2 25
11.5%
-64.8%
Q1 25
31.2%
-102.6%
Q4 24
22.9%
-74.3%
Q3 24
-14.1%
-94.6%
Q2 24
7.4%
-79.1%
Q1 24
25.3%
-151.9%
Net Margin
NWN
NWN
RARE
RARE
Q4 25
-62.0%
Q3 25
-18.1%
-112.8%
Q2 25
-1.1%
-69.0%
Q1 25
17.8%
-108.5%
Q4 24
-80.9%
Q3 24
-19.8%
-95.7%
Q2 24
-1.3%
-89.5%
Q1 24
14.7%
-156.8%
EPS (diluted)
NWN
NWN
RARE
RARE
Q4 25
$1.38
$-1.28
Q3 25
$-0.73
$-1.81
Q2 25
$-0.06
$-1.17
Q1 25
$2.18
$-1.57
Q4 24
$1.12
$-1.34
Q3 24
$-0.71
$-1.40
Q2 24
$-0.07
$-1.52
Q1 24
$1.69
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NWN
NWN
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$36.7M
$421.0M
Total DebtLower is stronger
$2.4B
Stockholders' EquityBook value
$1.5B
$-80.0M
Total Assets
$6.2B
$1.5B
Debt / EquityLower = less leverage
1.65×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NWN
NWN
RARE
RARE
Q4 25
$36.7M
$421.0M
Q3 25
$32.2M
$202.5M
Q2 25
$102.6M
$176.3M
Q1 25
$100.0M
$127.1M
Q4 24
$38.5M
$174.0M
Q3 24
$35.0M
$150.6M
Q2 24
$65.2M
$480.7M
Q1 24
$72.4M
$112.3M
Total Debt
NWN
NWN
RARE
RARE
Q4 25
$2.4B
Q3 25
$2.2B
Q2 25
$2.2B
Q1 25
$2.2B
Q4 24
$1.7B
Q3 24
$1.6B
Q2 24
$1.6B
Q1 24
$1.6B
Stockholders' Equity
NWN
NWN
RARE
RARE
Q4 25
$1.5B
$-80.0M
Q3 25
$1.4B
$9.2M
Q2 25
$1.5B
$151.3M
Q1 25
$1.5B
$144.2M
Q4 24
$1.4B
$255.0M
Q3 24
$1.4B
$346.8M
Q2 24
$1.3B
$432.4M
Q1 24
$1.3B
$140.3M
Total Assets
NWN
NWN
RARE
RARE
Q4 25
$6.2B
$1.5B
Q3 25
$5.9B
$1.2B
Q2 25
$5.8B
$1.3B
Q1 25
$5.7B
$1.3B
Q4 24
$5.2B
$1.5B
Q3 24
$4.9B
$1.5B
Q2 24
$4.8B
$1.6B
Q1 24
$4.8B
$1.3B
Debt / Equity
NWN
NWN
RARE
RARE
Q4 25
1.65×
Q3 25
1.56×
Q2 25
1.53×
Q1 25
1.53×
Q4 24
1.23×
Q3 24
1.16×
Q2 24
1.17×
Q1 24
1.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NWN
NWN
RARE
RARE
Operating Cash FlowLast quarter
$3.3M
$-99.8M
Free Cash FlowOCF − Capex
$-131.0M
$-100.8M
FCF MarginFCF / Revenue
-33.2%
-48.6%
Capex IntensityCapex / Revenue
34.1%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-197.8M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NWN
NWN
RARE
RARE
Q4 25
$3.3M
$-99.8M
Q3 25
$-15.9M
$-91.4M
Q2 25
$102.2M
$-108.3M
Q1 25
$179.6M
$-166.5M
Q4 24
$-19.4M
$-79.3M
Q3 24
$-26.4M
$-67.0M
Q2 24
$121.0M
$-77.0M
Q1 24
$125.0M
$-190.7M
Free Cash Flow
NWN
NWN
RARE
RARE
Q4 25
$-131.0M
$-100.8M
Q3 25
$-125.9M
$-92.7M
Q2 25
$-18.3M
$-110.7M
Q1 25
$77.4M
$-167.8M
Q4 24
$-119.6M
$-79.5M
Q3 24
$-121.7M
$-68.6M
Q2 24
$4.3M
$-79.0M
Q1 24
$42.8M
$-193.9M
FCF Margin
NWN
NWN
RARE
RARE
Q4 25
-33.2%
-48.6%
Q3 25
-76.4%
-58.0%
Q2 25
-7.8%
-66.5%
Q1 25
15.7%
-120.5%
Q4 24
-32.2%
-48.3%
Q3 24
-88.9%
-49.2%
Q2 24
2.0%
-53.7%
Q1 24
9.9%
-178.2%
Capex Intensity
NWN
NWN
RARE
RARE
Q4 25
34.1%
0.5%
Q3 25
66.8%
0.8%
Q2 25
51.0%
1.5%
Q1 25
20.7%
1.0%
Q4 24
27.0%
0.1%
Q3 24
69.6%
1.2%
Q2 24
55.1%
1.4%
Q1 24
19.0%
3.0%
Cash Conversion
NWN
NWN
RARE
RARE
Q4 25
Q3 25
Q2 25
Q1 25
2.04×
Q4 24
Q3 24
Q2 24
Q1 24
1.96×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NWN
NWN

NWN Gas Utility$341.4M87%
Alternativerevenue$27.2M7%
Si Energy Gas Utility$20.0M5%
NW Natural Other$6.9M2%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons